{"id":"abiraterone-with-prednisone-or-enzalutamide","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Hypertension"},{"rate":"15-25","effect":"Hypokalemia"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Hot flashes"},{"rate":"15-25","effect":"Diarrhea"},{"rate":"15-25","effect":"Nausea"},{"rate":"10-20","effect":"Edema"},{"rate":"5-10","effect":"Cardiac arrhythmia"},{"rate":"0.5-1","effect":"Seizure (enzalutamide)"}]},"_chembl":{"chemblId":"CHEMBL1082407","moleculeType":"Small molecule","molecularWeight":"464.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Abiraterone acetate is a prodrug that inhibits 17α-hydroxylase/17,20-lyase (CYP17A1), a key enzyme in testosterone and DHEA synthesis in the adrenal glands and tumor cells, reducing circulating androgens. Enzalutamide is an androgen receptor antagonist that blocks AR signaling in prostate cancer cells. Prednisone is co-administered with abiraterone to suppress ACTH-driven mineralocorticoid production and manage associated hypertension and hypokalemia. Together, these agents provide dual suppression of androgen production and receptor signaling in castration-resistant prostate cancer.","oneSentence":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:58:35.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"},{"name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)"}]},"trialDetails":[{"nctId":"NCT06136650","phase":"PHASE3","title":"A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-18","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms","enrollment":1314},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT06136624","phase":"PHASE3","title":"Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-12-31","conditions":"Prostate Cancer Metastatic","enrollment":1310},{"nctId":"NCT05751941","phase":"PHASE2","title":"Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-02-14","conditions":"Prostate Cancer, Metastatic Prostate Cancer","enrollment":26},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT04876651","phase":"PHASE3","title":"The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only","status":"TERMINATED","sponsor":"Telix Pharmaceuticals (Innovations) Pty Ltd","startDate":"2023-08-29","conditions":"Metastatic Prostate Cancer","enrollment":16},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT05818683","phase":"PHASE1","title":"A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-04-26","conditions":"Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer","enrollment":277},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174},{"nctId":"NCT06764485","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-03-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":960},{"nctId":"NCT04647526","phase":"PHASE3","title":"Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company","startDate":"2021-02-25","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":455},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT02960022","phase":"PHASE2","title":"A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2016-12-22","conditions":"Prostate Cancer","enrollment":900},{"nctId":"NCT03480646","phase":"PHASE1, PHASE2","title":"ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Constellation Pharmaceuticals","startDate":"2017-11-15","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":175},{"nctId":"NCT04787744","phase":"PHASE2, PHASE3","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-07-01","conditions":"Prostate Cancer, Oligometastasis, Oligorecurrence","enrollment":464},{"nctId":"NCT05588609","phase":"PHASE2","title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","status":"TERMINATED","sponsor":"Merus B.V.","startDate":"2022-11-17","conditions":"NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer","enrollment":13},{"nctId":"NCT03860987","phase":"PHASE2","title":"Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-04-30","conditions":"Castrate Sensitive Prostate Cancer","enrollment":12},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT05204927","phase":"PHASE3","title":"177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Curium US LLC","startDate":"2022-02-14","conditions":"Metastasis From Malignant Tumor of Prostate","enrollment":439},{"nctId":"NCT02975934","phase":"PHASE3","title":"A Study of Rucaparib Versus Physician's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency","status":"COMPLETED","sponsor":"pharmaand GmbH","startDate":"2017-06-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":405},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT04262154","phase":"PHASE2","title":"Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-03-03","conditions":"Metastatic Prostate Cancer","enrollment":28},{"nctId":"NCT03764540","phase":"PHASE2","title":"Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2019-04-01","conditions":"Metastatic Prostate Cancer","enrollment":57},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06652607","phase":"","title":"PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-12-20","conditions":"Prostate Cancer, Metastatic Cancer, Castrate Sensitive Prostate Cancer","enrollment":152},{"nctId":"NCT02663193","phase":"","title":"Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2015-12","conditions":"Prostate Cancer","enrollment":108},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT06496581","phase":"PHASE3","title":"Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-09-12","conditions":"Prostate Cancer Metastatic","enrollment":500},{"nctId":"NCT03148795","phase":"PHASE2","title":"A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-07-04","conditions":"Prostate Cancer","enrollment":128},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT01949337","phase":"PHASE3","title":"Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-01-22","conditions":"Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":1311},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT00268476","phase":"PHASE2, PHASE3","title":"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical Research Council","startDate":"2005-07-08","conditions":"Prostate Cancer","enrollment":11992},{"nctId":"NCT04139772","phase":"PHASE3","title":"Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-09-01","conditions":"Metastatic Castration-resistent Prostate Cancer","enrollment":18},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT03295565","phase":"PHASE2, PHASE3","title":"Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-05-07","conditions":"Prostate Cancer Metastatic, Metastasis","enrollment":100},{"nctId":"NCT03551782","phase":"PHASE1","title":"A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-06-28","conditions":"Castration-Resistant Prostatic Neoplasms","enrollment":33},{"nctId":"NCT02125357","phase":"PHASE2","title":"Sequencing Abiraterone and Enzalutamide in mCRPC","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2014-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":202},{"nctId":"NCT01946165","phase":"PHASE2","title":"Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-10-31","conditions":"Prostate Cancer","enrollment":69},{"nctId":"NCT02758132","phase":"PHASE2","title":"Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases","status":"TERMINATED","sponsor":"University of Hawaii","startDate":"2016-03-01","conditions":"Prostate Cancer","enrollment":1},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT02379390","phase":"PHASE2","title":"Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide","status":"TERMINATED","sponsor":"Sanofi","startDate":"2015-06-17","conditions":"Prostate Cancer Metastatic","enrollment":8},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028},{"nctId":"NCT02380313","phase":"PHASE1","title":"Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2015-10","conditions":"Cancer","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4399,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Abiraterone with Prednisone or Enzalutamide","genericName":"Abiraterone with Prednisone or Enzalutamide","companyName":"Curium US LLC","companyId":"curium-us-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone inhibits CYP17A1 to block androgen synthesis, while enzalutamide antagonizes the androgen receptor, together suppressing testosterone-driven prostate cancer growth; prednisone provides glucocorticoid support to mitigate mineralocorticoid excess from abiraterone. Used for Metastatic castration-resistant prostate cancer (mCRPC), Non-metastatic castration-resistant prostate cancer (nmCRPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}